| Literature DB >> 33281191 |
Sara Ciceri1, Rafaela Montalvão-de-Azevedo1,2, Filippo Spreafico3, Daniela Perotti4, Amir Tajbakhsh1,5,6, Alessia Bertolotti7, Rosalin Dolores Spagnuolo7, Luna Boschetti3, Maria Capasso8, Paolo D'Angelo9, Annalisa Serra10, Francesca Diomedi-Camassei11, Mariaclaudia Meli12, Marilina Nantron13, Paola Quarello14, Anna Maria Buccoliero15, Angela Tamburini16, Chiara Maura Ciniselli17, Paolo Verderio17, Paola Collini7, Paolo Radice1.
Abstract
Whereas 90% of patients with Wilms tumor (WT) reach cure, approximately half of patients developing a recurrent tumor die of the disease. Therefore, to disclose events leading to recurrence represents a clinical need. To study paired primary/recurrent tumor samples, being aware of the intra-tumoral heterogeneity, might help finding these answers. We previously suggested that mutations in SIX1 and DROSHA underlie WT recurrence. With the aim to better investigate this scenario, we collected 19 paired primary/recurrent tumors and 10 primary tumors from relapsing patients and searched for mutations in the SIX1/2 genes and microRNA processing genes (miRNAPGs). We found SIX1 mutation in one case, miRNAPGs mutations in seven cases, and the co-occurrence of SIX1 and miRNAPG mutations in one case. We could observe that, whereas in primary tumors the mutations could be heterogeneously present, in all cases they were positively selected and homogeneously present in the recurrent disease, as also indicated by a "moderate" and "almost perfect" agreement (according to the Landis and Koch classification criteria) between paired samples. Analysis of SIX1/2 genes and miRNAPGs in 50 non-relapsing WTs disclosed SIX2 mutation in one case and miRNAPGs mutations in seven. A borderline statistically significant association was observed between miRNAPGs mutations and the occurrence of relapse (p value: 0.05). These data suggest that SIX1 and miRNAPGs mutations may provide an advantage during tumor progression to recurrence and can represent oncogenic drivers in WT development.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33281191 DOI: 10.1038/s41417-020-00268-3
Source DB: PubMed Journal: Cancer Gene Ther ISSN: 0929-1903 Impact factor: 5.987